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Down syndrome (DS) is the most genetic cause of mental retardation and is caused by the triplication of chromosome 21. In
addition to the disabilities caused early in life, DS is also noted as causing Alzheimer’s-disease-like pathological changes in the
brain, leading to 50–70% of DS patients showing dementia by 60–70 years of age. Inflammation is a complex process that has a
key role to play in the pathogenesis of Alzheimer’s disease. There is relatively little understood about inflammation in the DS brain
and how the genetics of DS may alter this inflammatory response and change the course of disease in the DS brain. The goal of
this review is to highlight our current understanding of inflammation in Alzheimer’s disease and predict how inflammation may
affect the pathology of the DS brain based on this information and the known genetic changes that occur due to triplication of
chromosome 21.
1. Introduction
Down syndrome (DS) is the most common chromosomal
anomaly among live-born infants and is the most frequent
genetic cause of mental retardation [1, 2], with an incidence
of one per 733 live births in the United States [3]. DS is
caused by a triplication of chromosome 21 (a full list of genes
located on chromosome 21 can be found in [4]). Due to the
extensive number of genes triplicated, there is an extremely
high incidence of congenital cardiac and gastrointestinal
abnormalities [5]. DS is usually detected during pregnancy
through first-trimester screening tests followed up by confir-
mation through amniocentesis, chorionic villus sampling, or
percutaneous umbilical blood sampling [6].
Alzheimer’s disease (AD) is the leading cause of dementia
and is characterized clinically by a progressive loss of
memory and cognition. An absolute diagnosis of AD can
only occur after pathological analysis is performed on the
brain tissue. There are two signature pathological lesions
required for diagnosis; neuritic plaques composed of aggre-
gated amyloid-β (Aβ) peptides, and neurofibrillary tangles
composed of hyperphosphorylated, aggregated tau protein
[7]. AD is usually considered a disease of aging, where
currently 1 in 8 Americans over the age of 65 have AD yet
half of those over 85 years have AD (data obtained from the
Alzheimer’s Association; www.alz.org).
In DS, Aβ deposits begin to accumulate in childhood and
increase progressively with age [8]. There is an acceleration
of this pathology between the ages of 35–45 years when
other AD pathologies begin to occur, most importantly
neurofibrillary tangles and inflammation [9]. Despite the
certainty of developing AD-like pathologies in DS by mid-
life, the onset of dementia is less certain. The consensus
from a number of studies is that 50–70% of DS individuals
will develop dementia by ages 60–70 years [10–13]. The
reason individuals with DS develop Aβ deposits early in life
is primarily due to the presence of some AD-related genes
on chromosome 21, and hence these genes are triplicated in
most cases of DS. Of the AD-associated genes triplicated in
DS, the critical ones are amyloid precursor protein (APP)
and β-amyloid cleavage enzyme 2 (BACE2). Aβ peptide is a
cleavage product of APP. APP is a transmembrane protein
and is differentially cleaved by enzymes called secretases of
which there exist α-secretase, β-secretase (BACE), and γ-
secretase. When β-secretase and γ-secretase cleave APP Aβ is
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a product, when α-secretase cleaves, this occurs in the middle
of the Aβ portion and other peptides are produced.
Inflammation is known to occur in the brains of both
AD and DS patients in response to the presence of neuritic
plaques and neurofibrillary tangles. This inflammation is
primarily mediated by microglial cells, although other glial
cells and even neurons participate in this inflammatory
response. It is becoming increasingly clear in the AD field
that inflammation can directly influence plaques and tangles
in the same way that plaques and tangles can directly influ-
ence inflammation. The purpose of this review is to discuss
the evolving understanding of neuroinflammation in AD and
determine how this may relate to the pathophysiology of DS.
2. Neuroinflammation in Alzheimer’s Disease
Neuroinflammation is a complex process with many phe-
notypically varied states. The primary inflammatory cell in
the brain is the microglial cell, which was first identified as
a unique cell subtype by Del Rio Hortega in the 1920s. The
microglial cell has been described as an ameboid-like cell that
can be labeled immunocytochemically using macrophage
cell surface markers [14, 15]. Other cells in the brain can
contribute to the inflammatory response as well as microglia,
although this contribution is considered to be significantly
less than that of the microglia. Astrocytes and neurons can
participate in the neuroinflammatory process as well as
oligodendrocytes and vascular pericytes [16].
The view of neuroinflammation in the brain, and in dis-
orders of the brain, has evolved over time, and continues to
evolve as our understanding of the capabilities of the system
grows. While once considered “immunologically privileged,”
the brain is now known to exhibit an almost complete spec-
trum of inflammatory responses given the correct stimuli
and environment. While once considered a cytotoxic loop
[17], there are now examples of harnessing the inflammatory
system of the brain to ameliorate AD pathologies and
improve outcomes (see further discussion later in this sec-
tion).
In AD, microglia expressing some classic activation
markers such as MHC-II (associated with antigen presenta-
tion), CD68 (a lysosomal protein), and CD36 (a class B scav-
enger receptor) are highly localized to the area immediately
surrounding an amyloid plaque or neurofibrillary tangle
[18]. While this led some to hypothesize that this reaction
was contributing to the toxicity of these pathologies, others
suggested that the microglia may be performing a beneficial
function in removing the abnormal protein deposits from
the brain. As yet, there is no consensus, and it is likely
that both phenomena are occurring to differing degrees. To
better understand these processes, researchers turned to the
assessment of cytokines to determine the function(s) of these
microglial cells.
In AD, many cytokines have been found to be altered.
Among those, the most common are IL-1β, IL-6, TNFα, and
TGFβ. IL-1β was first shown by Griffin et al. in 1995 to be
associated with the development of neuritic amyloid plaques
from diffused deposits using human postmortem tissue [19].
Later, Griffin et al. expanded their findings to develop a
“cytokine cycle” hypothesis that suggested the IL-1β pro-
duction in response to amyloid deposits initiated a series of
events including increased APP production and processing
by neurons, recruitment of astrocytes, and activation of these
astrocytes leading to signaling in the microglia inducing
yet further IL-1β [20]. IL-1β induces S100β production in
astrocytes [21], which is a cytokine that promotes neurite
growth [22]. Most recently, serum IL-1β has been found to
be elevated in cases of mild cognitive impairment (MCI)
that has a higher risk for conversion to dementia, possibly
indicating that serum IL-1β may be useful for identify-
ing those MCI patients at risk for converting to AD [23].
Also, there are genome-wide association studies (GWASs)
that have identified IL-1β polymorphisms associated with
AD (reviewed in [24]). It will require further studies and
analyses to determine whether these polymorphisms, are,
in fact, associated with AD risk. However, in contrast to
the negative data presented with respect to IL-1β, there
is more recent data showing that IL-1β overexpression in
the hippocampus of transgenic mice results in amelioration
of amyloid pathology. IL-1β was increased specifically in
a single hippocampus of an APP/PS1 transgenic mouse
by genetic means and this hippocampus showed a 50%
reduction in plaque load [25].
IL-6 is another cytokine that mediates immune responses
and inflammatory reactions [26]. While microglia are the
main source of IL-6 in the CNS, astrocytes, neurons, and
endothelial cells are all capable of producing the cytokine
[27–29]. In AD, brain tissue IL-6 has been shown to be
elevated in pathologically relevant regions [30]. While much
of the focus on IL-6 has been on its destructive effects such
as induction of acute-phase proteins, increasing vascular
permeability, activation of lymphocytes, and antibody syn-
thesis (reviewed in [31]), there are some positive effects of
IL-6 that may play a role in AD. This includes enhancing
neuronal survival [32–34] and suppressing demyelination in
a model of multiple sclerosis [35]. Moreover, in a mouse
model of amyloid deposition, Chakrabarty et al. showed that
overexpression of IL-6 enhanced microglial phagocytosis of
amyloid deposits and, therefore, ameliorated amyloid burden
[36].
TNFα is another cytokine that has been shown to have
both beneficial and detrimental effects in the CNS. It acts
as a highly potent proinflammatory and cytotoxic molecule
in conditions of the CNS [37–40]. In contrast, TNFα has
been shown to have trophic effects on hippocampal neurons
[41] and provide protection from free-radical damage in
primary neurons [42]. It is thought that the source of such
dichotomous effects is the receptor subtype through which
the TNFα is acting. There are two primary receptors for
TNFα in the CNS; TNFα receptor 1 (TNFR1) and TNFα
receptor 2 (TNFR2) [43]. TNFR1 mediates neuronal death
via the TNF-receptor-associated death domain protein and
caspase-8-activated apoptosis [44, 45]. TNFR2 is thought to
mediate the beneficial, prosurvival action of TNFα through
the nuclear factor-κB- (NFκB-)mediated antiapoptotic path-
way [46]. This is likely an oversimplified view of the actions
of TNFα through its receptors and there have been many
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subtleties of these systems described in the literature. In AD,
it has been shown that expression of TNFR1 is elevated
in the brain while levels of TNFR2 are decreased [44]. In
addition, clinical trials are ongoing for the treatment of AD
with etanercept, a fusion protein combining TNFR2 and the
Fc portion of IgG used to treat Crohn’s disease and arthritis
as well as other autoimmune disorders [47]. Etanercept acts
as a decoy receptor for TNF, reducing the effects of TNF at the
biologically active receptors. Preliminary studies showed that
perispinal delivery of etanercept in a small number of AD
patients improved cognition [48]. In addition, thalidomide is
also currently in clinical trials for AD based on its anti-TNFα
effects. In transgenic mice, thalidomide has been shown to
improve learning and memory [49].
Finally, TGFβ is a growth factor that has been shown to
play a prominent role in tissue development, homeostasis,
and repair [50]. Unlike the cytokines discussed to this point,
TGFβ is associated mostly with repair mechanisms and is
not known for its damaging or cytotoxic actions in the
CNS. Instead, it is mostly associated with the formation of
a glial scar [51] and upregulation of extracellular matrix
proteins [52–54]. In AD, TGFβ levels are increased in the
brain [55] but decreased in serum [56]. In APP transgenic
mice, overproduction of TGFβ by astrocytes results in lower
parenchymal amyloid deposits but increased deposition
of amyloid in the cerebrovasculature [57]. Most recently,
Tesseur et al. have shown that deficiencies exist in TGFβ
signaling in the human AD brain, and these deficiencies can
lead to enhanced AD pathology and associated neurodegen-
eration [58].
There is a rapidly growing interest in better character-
izing the inflammatory state in the brain, and especially in
AD. A paper by Colton et al. in 2006 described “classical
activation” and “alternative activation” of microglia in the
brain [59]. Classical activation was used to describe the Th1
cytokines such as IFNγ, IL-1β, TNFα, and IL-6. Alternative
activation was used to describe a state associated with anti-
inflammatory, repair, and wound healing effects mediated
by IL-10, TGFβ, IL-4, IL-13, arginase 1 (AG1), and tissue
remodeling factors Found in Inflammatory Zone 1 (FIZZ1)
and chitinase 3-like 3 (YM1). This paper showed that cul-
tured microglial cells, transgenic mouse models of AD,
and postmortem tissue from human AD brains all showed
expression of both classical and alternative activation mark-
ers. Most interesting was that alternative activation markers
were expressed to the same degree, sometimes more than
the classical activationmarkers commonly associated with an
inflammatory response.
We have now expanded on the concept of multiple
activation states to include a full spectrum of macrophage
responses. Shown in Figure 1 are the four distinct inflamma-
tory states we are currently studying in the brain. These states
are well characterized in the peripheral macrophage litera-
ture (reviewed in [60, 61]). The M1 response is stimulated
by IFNγ and/or TNFα and is characterized by traditional
inflammatory cytokines IL-1β, IL-6, and IL-12. Broadly,
the M2 response represents the alternative activation state
described by Colton et al. We can further categorize this
state into M2a, M2b, and M2c. Each subtype of M2 response
has distinct stimuli and responses. IL-4 and/or IL-13 initiate
an M2a response that is characterized by tissue remodeling
factors FIZZ and YM1 as well as AG1 and mannose receptor
C1 (MRC1). Immune complexes stimulate anM2b response,
which is a specific response that has components of both M1
and M2a states. Finally, IL-10 stimulates an M2c response,
which is sometimes called an acquired deactivation state. The
M2c response is characterized by a series of markers that
actively antagonize M1 signaling pathways. By categorizing
the inflammatory response into these distinct types where
each stimuli and marker is established, we can better
understand what role(s) each state plays in AD progression
and therapy.
Drug development for the treatment of AD has recently
been harnessing the inflammatory component of the dis-
ease for treatment. The most interesting approach is
immunotherapy for AD. First demonstrated in 1999 [62],
immunotherapy uses either an active vaccination approach
or passive immunization to introduce anti-Aβ antibodies in
patients (reviewed in [63]). These anti-Aβ antibodies then
result in reductions in Aβ in the brain and ultimately, at least
in transgenic mouse models, improvements in learning and
memory [64, 65]. Injection of anti-Aβ antibodies directly
into the brains of transgenic mouse models showed a
dependence of amyloid removal on microglial activation
[66, 67]. Later studies systemically administering anti-Aβ
antibodies also showed a transient activation of microglia
[68] and a reduced efficacy when the antibody was deglyco-
sylated; a process that renders the IgG molecule incapable of
interacting with effector cells such as microglia [69].
Another approach that targets the inflammatory re-
sponse is the administration of nonsteroidal anti-inflamma-
tory drugs (NSAIDs). NSAIDs showed great promise in
retrospective epidemiological studies finding significant pro-
tection from AD with long-term NSAID use [70]. However,
a prospective clinical trial performed by NIA/NIH, called
the ADAPT trial, failed to show any significant benefit [71].
The NSAID story was furthermore clouded because some
NSAIDs also possessed γ-secretase modifying properties
that shifted APP cleavage to promote Aβ38 production,
as opposed to Aβ40 or Aβ42 [72]. The NSAIDs found to
have this activity were not included in the NIA/NIH trial.
However, it was recently found that a subset of patients
in the ADAPT trial did, in fact, benefit from NSAID use.
Naproxen attenuated cognitive decline in a subgroup of AD
patients termed “slow decliners,” whereas cognitive decline
was accelerated in those termed “fast decliners” [73]. It is
unclear why this would be the case, however, it is possible that
different inflammatory states may exist in these different AD
cases; some benefit from NSAIDs while some do not. Future
studies will examine whether this is, indeed, the case.
3. Neuroinflammation in Down’s Syndrome
While many of the pathways of inflammation described for
AD will be directly relevant to DS, there are some critical
inflammatory genes on chromosome 21 that will be tripli-
cated in DS and may, therefore, influence the inflammatory
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Figure 1: Schematic showing the four distinct states of inflammation possible in response to a stimuli in microglial/macrophage cells.
state of the DS brain. We will discuss those factors in this
review and take our current knowledge of inflammatory
states in other neurological disorders to predict how these
may be playing a role in DS. Table 1 shows the inflammatory-
associated genes that are found on chromosome 21 and are
triplicated in most DS patients. We will discuss each of these
factors and their impact on the inflammatory balance of the
brain.
CXADR is a gene encoding for a protein called coxsackie
virus and adenovirus receptor (herein abbreviated CXADR).
CXADR has a dual function as a viral receptor and an
adhesion molecule associated with tight junctions. It is
highly expressed in brain as well as systemic secretory organs
such as the pancreas, testis, and small intestine [74]. In
the heart, CXADR is increased in models of myocardial
inflammation and cardiac injury in the absence of viral
infection suggesting that there is an innate role of this protein
in the inflammatory response [75]. Recently, it was shown
that CXADR can induce stress-activated mitogen-activated
protein kinase (MAPK) pathways in the heart leading to
increased production of IFNγ, IL-12, IL-1β, TNFα, and
IL-6 [76]. One can predict then that increased expression
of CXADR in Down’s syndrome may contribute to an
overactivated M1 inflammatory response, since all of these
inflammatory cytokines induced by CXADR are associated
with an M1 response. In addition, CXADR has a significant
role in tight junction function where, in endothelial cells, it
facilitates transendothelial migration of neutrophils [77]. If
CXADR expression is altered on the endothelial cells of the
cerebrovasculature in DS patients, then there may be altered
infiltration of peripheral inflammatory cells into the brain
influencing the inflammatory response.
Two members of the ADAMTS (a disintegrin and metal-
loproteinase with thrombospondin motif) family are located
on chromosome 21 and, therefore, subject to triplication
in DS, ADAMTS1, and ADAMTS5. ADAMTS1 contains
a signal peptide in the N-terminal region indicating it is
secreted [78]. It acts as a proteinase degrading extracellular
matrix proteoglycans such as aggrecan and versican [79].
ADAMTS5 is also a proteinase and shares the same substrates
as ADAMTS1 [80]. Both ADAMTS1 and ADAMTS5 can
be induced by IL-1β, indicating a dependence on an
inflammatory response [81, 82]. It has been shown in DS
that ADAMTS1 is five-fold overexpressed at the protein
level, while ADAMTS5 was not significantly increased by
Western blot measurements [83]. Given the induction by
inflammatory cytokine IL-1β, one could hypothesize that the
triplication of these proteinases would lead to exacerbated
degradation of extracellular matrix proteins in response to
an inflammatory insult. In addition, Griffin et al. showed that
DS brain has greater IL-1β immunoreactivity indicating that
there is more IL-1β present in the DS brain to stimulate the
ADAMTSs [84].
T-cell lymphoma invasion and metastasis 1 (TIAM1) is
a guanine nucleotide exchange factor for Rac1 [85] and,
therefore, contributes to the activation of Rac1, which is
necessary for the activation of NADPH oxidase [86]. Most
recently, Tiam1 was found to be a critical regulatory factor
in cytokine-induced induction of NADPH oxidase, more
specifically, induction by IL-1β [87]. While these data used
pancreatic β-cells, one could predict that overexpression of
Tiam1 in the DS brain could lead to increased oxidative stress
in response to an inflammatory insult that involves IL-1β.
Indeed, it has been shown that Tiam1 protein expression is
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Table 1: A summary of the inflammation-related genes located on chromosome 21.
Gene Protein Function Ref
CXADR Coxsackie virus and adenovirus receptor
Activation of JNK and p38-MAPK pathways leading to
production of M1 cytokines.
[76]
ADAMTS1
ADAMmetalloproteinase with thrombospondin
type 1 motif, 1
Secreted protease known to be induced by IL-1β [81]
ADAMTS5
ADAMmetalloproteinase with thrombospondin
type 1 motif, 5
Secreted protease known to be induced by IL-1β and
TGFβ.
[82]
TIAM1 T-cell lymphoma invasion and metastasis 1
Necessary for cytokine-mediated generation of
oxidative species through NADPH oxidase.
[87]
SOD1 Superoxide dismuatose 1 Scavenges superoxide radicals producing H2O2 and O2. [109]
IFNAR2 Interferon (alpha, beta, and omega) receptor 2
Activates JAK/STAT-mediated pathway in response to
IFNα/β.
[110]
IFNAR1 Interferon (alpha, beta, and omega) receptor 1
Activates JAK/STAT-mediated pathway in response to
IFNα/β.
[110]
IFNGR2 Interferon gamma receptor 2
Activates JAK/STAT-mediated pathway in response to
IFNγ.
[111]
RIPK4 Receptor-interacting serine-threonine kinase 4 Necessary for signaling through TNFR1 [96]
CBS Cystathione-beta-synthase
Production of hydrogen sulfide (H2S); a regulator of
inflammation
[112]
S100B S100 calcium binding protein B
Constitutive expression by astrocytes, released in
response to TNFα
[113]
PRMT2 Protein arginine methyltransferase 2 Blocks the actions of NFκB in the nucleus [114]
increased in fetal DS brain compared to control fetal brain
[88].
Superoxide dismutase 1 (SOD1) binds copper and zinc
and is a potent endogenous antioxidant. The enzyme is a
soluble cytoplasmic and mitochonidral interspace protein
that converts superoxide radicals to molecular oxygen and
hydrogen peroxide [89]. Mutations in the SOD1 gene
are commonly associated with genetic susceptibility to
anterolateral sclerosis (ALS) [90]. While the hypothesis for
the role of these mutations centered on the potential loss
of function, and, therefore, increased oxidative stress, there
has been increasing evidence to discount this hypothesis
including the lack of ALS symptoms or pathology in SOD1
knockout mice [91]. It is unclear what the consequence is of
overexpression of nonmutant SOD1 as would occur in DS.
In a model of retinitis pigmentosa, it was found that loss of
SOD1 worsened the outcomes. However, when SOD1 was
overexpressed in this model, the levels of oxidative damage
were actually worse. The authors found that in the absence
of a peroxide-detoxifying enzyme in the same cellular
compartment, overexpression of SOD1 actually causes more
oxidative stress [92]. It could be suggested that the same
may be the case in DS if the triplication of SOD1 results in
overexpression of the protein in the absence of an increased
level of peroxide-detoxifying enzyme.
Interferon receptors IFNAR1, IFNAR2, and IFNGR2 are
all located on chromosome 21 and are, therefore, all subject
to triplication in most cases of DS. IFNAR1 and IFNAR2
both respond to IFNα, IFNβ, or IFNo and, upon ligand
binding, activate the JAK/STAT signaling pathway leading to
induction of proinflammatory gene expression such as IL-1β,
TNFα, and IL-6. IFNGR2 uses the same signaling pathway
but responds to IFNγ specifically. A mouse model for the
study of DS, the trisomy 16 mouse, includes triplication
of IFNGR2 and IFNAR2. These mice develop significant
pathology in utero and rarely survive to birth. Studies in
these mice have shown that anti-IFN IgG treatment of fetuses
improves the mouse phenotype suggesting the triplication
of the IFN receptors significantly contributes to the severe
pathology present in these mice [93]. The same group later
showed that introducing a partial knockout of the IFNAR2
and IFNGR2 can improve growth and viability of cultured
neurons derived from the trisomy 16 mouse fetuses [94].
Since these genes are triplicated in DS, it is likely that there is
a hyperresponsiveness to IFN in the DS patient that may lead
to an increased inflammatory response, both in the brain and
systemically.
Receptor-interacting serine-threonine kinase 4 (RIPK4)
is a protein kinase involved in multiple cell signaling
pathways. One of these pathways is the signaling pathway for
the activation of NFkB [95]. In addition, RIPK4 is involved in
the signaling cascade of the TNFα receptor TNFR1 [96]. It is
important to note that the TNFR1 is most heavily implicated
with the toxic effects of TNFα and it could be predicted
that overexpression of RIPK4 may increase responsiveness of
TNFR1 to TNFα exacerbating the effects of TNFR1. At this
time, however, this is purely speculative.
Cytathione beta synthase (CBS) is a cytosolic enzyme
that catalyzes the desulfhydration of cysteine-producing
hydrogen sulfide (H2S). H2S is now recognized as an atypical
cellular messenger that has many normal physiological
functions [97]. CBS binds NO or CO in its heme pocket and
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Figure 2: Schematic illustrating our hypothesis for the role of inflammation in Down syndrome.
this bindingmodulates the activity of the enzyme [98]. H2S is
a complicated signaling molecule with an apparent bimodal
action on inflammation, where low levels appear to be anti-
inflammatory, yet high levels may exacerbate inflammation
in some instances. There are several extensive reviews on H2S
signaling that discuss this phenomenon in great detail (see
[99, 100]). It remains unclear how the overexpression of CBS
in DS influences the DS pathology and whether the amount
of H2S produced in DS patients is of the anti-inflammatory
or proinflammatory concentrations.
S100β is a protein localized primarily to the brain where
it is expressed by astrocytes. It is secreted by astrocytes in
response to IL-1β and cyclic-AMP [101]. S100β is another
inflammatory mediator with dichotomous actions. At low
concentrations, it appears to enhance survival of neurons
[102] and stimulate neurite outgrowth [22]. In contrast,
high concentrations of S100β increases cell death [103] and
causes apoptosis [104]. It has been shown in DS brains
that S100 is greatly increased compared to control brain.
The concentrations would place the levels of S100β in the
toxic category, suggesting that the overexpression of S100β
in DS brain plays a negative role in the aging pathology
[84].
Protein arginine methytranferase 2 (PRMT2) is an
en-zyme that catalyzes the methylation of arginine. It
has been shown that arginine methylation is a means
of regulation of the JAK-STAT signaling pathway, which
is key for many inflammatory processes including IFNγ,
IFNα, and IL-6 [105]. In addition, natural degradation
of proteins containing methylated arginine results in the
production of asymmetric dimethylarginine (ADMA) [106].
ADMA is an endogenous inhibitor of nitric oxide syn-
thase (NOS), a key player in normal cell signaling and
inflammation [107]. It is unclear whether the triplica-
tion of PRMT2 results in significant changes in ADMA
concentrations in the brain, however, DS patients with
pulmonary hypertension do show increased ADMA con-
centrations compared to non-DS patients with pulmonary
hypertension [108]. If this were also true for the brain,
one could predict that there would be decreased production
of NO and increased activation of the JAK-STAT pathway,
both factors could influence the inflammatory state of the
brain.
4. Inflammation Hypothesis and
Future Directions.
We hypothesize that the triplication of chromosome 21 as
occurs in DS will result in a greatly exacerbated M1 inflam-
matory response. The basis for this hypothesis is the range
of genes that are found on chromosome 21 and, therefore,
triplicated. We have discussed each of the genes that are
relevant to inflammation above and have summarized what
these may mean to inflammation in Figure 2. Since most of
the genes are primarily associated with the M1 inflammatory
response, we predict that this is the main state that will
be enhanced in the DS brain. Triplication of the major
interferon receptors IFNAR1, IFNAR2, and IFNGR2 means
that there will be enhanced interferon signaling. In turn, this
enhanced signaling will increase production of M1 markers
IL-1β, TNFα, and IL-6.While these components are known
to result in oxidative stress, the triplication of TIAM1, SOD1,
and PRMT2 will greatly exacerbate this oxidative stress.
TIAM1 enhances oxidation by inducing NADPH oxidase,
SOD1 at high concentrations has been shown to enhance
oxidation, and PRMT2 inhibits nitric oxide production,
which acts as an antioxidant in the brain at physiologic
concentrations. All of these factors will combine to enhance
neurodegeneration in the DS brain in response to primary
pathologies such as amyloid plaques and neurofibrillary
tangles.
In considering inflammation in DS, there is a relative
lack of data relative to other disorders. While AD provides
us with significant background information on the role of
inflammation in the disease, it is clear that the condition of
DS, and the triplication of so many inflammatory-associated
genes, creates a unique inflammatory environment worthy
for further study. The data obtained through the study of
inflammation in DS will be essential to further not only
the study of DS but also, in turn, the normal inflammatory
pathways in neurodegenerative disorders.
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